or Try an Advanced Search...

    Technical Analysis for LUMO - Lumos Pharma, Inc.

    Grade Last Price % Change Price Change
    D 2.81 0.36% 0.01
    LUMO closed down 0.18 percent on Wednesday, April 24, 2024, on 2.35 times normal volume. It ran into resistance at its 50 day moving average.
    Earnings due: May 1
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical LUMO trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.54%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.54%
    Gapped Up Strength 0.54%
    Upper Bollinger Band Touch Strength 0.54%
    Crossed Above 20 DMA Bullish 0.36%
    Gapped Up Strength 0.36%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.85%
    MACD Bullish Signal Line Cross Bullish 4.85%
    NR7 Range Contraction 4.85%
    Inside Day Range Contraction 4.85%
    Older End-of-Day Signals for LUMO ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 3 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 4 hours ago
    Fell Below Previous Day's Low about 4 hours ago
    Down 2 % about 4 hours ago
    Down 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    LUMO Chart by TradingView
    Basic chart:

    Profile

    Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Genetic Diseases Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy

    Is LUMO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
    Mar 20 Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
    Mar 10 Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
    Mar 8 Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
    Mar 7 Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
    Mar 7 Lumos Pharma GAAP EPS of -$4.18 misses by $0.13, revenue of $2.05M beats by $0.83M
    Mar 7 Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
    Mar 7 Earnings Scheduled For March 7, 2024
    Mar 6 Lumos Pharma FY 2023 Earnings Preview
    Feb 26 Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
    See more LUMO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.55
    52 Week Low 2.41
    Average Volume 19,694
    200-Day Moving Average 3.12
    50-Day Moving Average 2.85
    20-Day Moving Average 2.70
    10-Day Moving Average 2.63
    Average True Range 0.18
    RSI (14) 54.13
    ADX 22.32
    +DI 27.36
    -DI 15.86
    Chandelier Exit (Long, 3 ATRs) 2.41
    Chandelier Exit (Short, 3 ATRs) 2.95
    Upper Bollinger Bands 2.92
    Lower Bollinger Band 2.47
    Percent B (%b) 0.72
    BandWidth 16.61
    MACD Line -0.04
    MACD Signal Line -0.07
    MACD Histogram 0.0249
    Fundamentals Value
    Market Cap 22.12 Million
    Num Shares 7.91 Million
    EPS -3.99
    Price-to-Earnings (P/E) Ratio -0.70
    Price-to-Sales 13.74
    Price-to-Book 0.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.11
    Resistance 3 (R3) 3.12 3.03 3.06
    Resistance 2 (R2) 3.03 2.94 3.02 3.04
    Resistance 1 (R1) 2.91 2.90 2.86 2.90 3.02
    Pivot Point 2.82 2.82 2.79 2.81 2.82
    Support 1 (S1) 2.70 2.73 2.65 2.69 2.57
    Support 2 (S2) 2.61 2.69 2.60 2.55
    Support 3 (S3) 2.49 2.61 2.53
    Support 4 (S4) 2.48